Helen Maddock

Professor

Accepting PhD Students

  • 706 Citations
  • 7 h-Index
20012019
If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Professor Helen Maddock has a PhD in Cardiovascular Pharmacology from Cardiff University (Welsh School of Pharmacy). She joined the University of Kent, Bioscience Department as a British Heart Foundation (BHF) funded post-doctoral research fellow, to work under Professors Simon Jarvis and Jeremy Pearson, where she characterised the nucleobase transporters in the heart and human endothelial cells. In 1998 she joined Professor Derek Yellon as a BHF post-doctoral research fellow and Honorary Lecturer, at the Hatter Cardiovascular Institute, part of the Institute of Cardiovascular Sciences, UCL, expanding her PhD studies by investigating intracellular signalling mechanisms associated with myocardial ischaemia-reperfusion injury. During this time she undertook studies using human cardiac tissue obtained from cardiac bypass graft patients.

 

In 2001, she was appointed as a Senior Lecturer in Cardiovascular Pharmacology & Physiology at Coventry University. Professor Maddock currently leads the successful Centre for Sport, Exercise and Life Sciences at Coventry University, in addition to being founder and Chief Scientific Officer of InoCardia Ltd, a Coventry University spin-out company. She has successfully led many research projects, building on experience originally gained in R&D within the pharmaceutical industry (AstraZeneca and GlaxoSmithKline) and academia. Professor Maddock has attracted research and commercial funding from the British Heart Foundation, Heart Research UK, British Pharmacological Society, European Regional Development Fund, Mercia Fund Management, Innovate UK, NC3Rs and the pharmaceutical industry. Her research is driven by the desire to improve cardiac health. Overall, she has made significant contributions to the field of cardiovascular biology, including original peer-reviewed articles, reviews and book chapters. Current research projects include the development of relevant non-clinical heart assays to assess cardiovascular disease related therapies using diseased and “healthy” human heart tissue and cells. In addition to this her team also undertakes clinical and non-clinical research and drug discovery strategies focussed on drug-induced cardiac injury and heart failure.

As Executive Director of the Centre for Sport, Exercise and Life Sciences, Professor Maddock is responsible for carrying out its mission and implementing its business plan. She also supervises basic and translational research, formulates and integrates research activities, and establishes programs that will foster public-private partnerships, philanthropy and commercialization of new drugs, devices and technology.

Research Interests

Cardiac contractile dysfunction ; Mitochondrial activity and energetic ; Drug-induced cardiotoxicity/Safety Pharmacology ; Myocardial stress adaptation and oxidative stress ; Human factor assessment using physiological techniques ; Identifying cardioprotective therapies for treating myocardial ischaemia/reperfusion injury ; Heart Failure

Vision Statement

The objective of my research is the understanding of the disease process and the intracellular signal transduction mechanisms and cellular stress responses that lead to cardiac contractile dysfunction and myocardial injury aligned to diabetes, heart failure and drug induced cardiotoxicity, with an aim to provide a rational basis for prevention or therapeutic intervention, including the involvement of biomarker identification. I have been instrumental in investigating the impact of mitochondrial function aligned to cardiovascular cellular stress responses, as evidenced by my publications. In addition I am currently in the process of exploiting the commercial aspect of my research and I have filed several priority patents to support the university spin-out company - InoCardia.

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 2 Similar Profiles
Adenosine A3 Receptors Medicine & Life Sciences
Myocardial Ischemia Medicine & Life Sciences
Wounds and Injuries Medicine & Life Sciences
Mitogens Medicine & Life Sciences
Phosphotransferases Medicine & Life Sciences
Doxorubicin Medicine & Life Sciences
Reperfusion Injury Medicine & Life Sciences
Reperfusion Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2001 2019

Ageing alters the severity of Sunitinib-induced cardiotoxicity: Investigating the mitogen activated kinase kinase 7 pathway association

Cooper, S., Sandhu, H., Hussain, A., Mee, C. & Maddock, H. 1 Jan 2019 In : Toxicology. 411, p. 49-59 11 p.

Research output: Contribution to journalArticle

Mitogens
Phosphotransferases
Aging of materials
Association reactions
sunitinib
3 Citations (Scopus)

Involvement of mitogen activated kinase kinase 7 intracellular signalling pathway in Sunitinib-induced cardiotoxicity

Sandhu, H., Cooper, S., Hussain, A., Mee, C. & Maddock, H. 1 Feb 2018 In : Toxicology. 394, p. 72-83

Research output: Contribution to journalArticle

Open Access
File
Mitogens
Phosphotransferases
MAP Kinase Kinase Kinase 5
sunitinib
Cardiotoxicity
3 Citations (Scopus)

Attenuation of Sunitinib-induced cardiotoxicity through the A3 adenosine receptor activation

Sandhu, H., Cooper, S., Hussain, A., Mee, C. & Maddock, H. 12 Aug 2017 In : European Journal of Pharmacology. (in press), p. (in press) 11 p.

Research output: Contribution to journalArticle

Open Access
File
Adenosine A3 Receptors
HL-60 Cells
MicroRNAs
Neoplasms
Publications
6 Citations (Scopus)
Open Access
File
Cardiovascular System
Pharmaceutical Preparations
Papillary Muscles
Risk Management
Heart Atria
24 Citations (Scopus)
Open Access
File
Adenosine A3 Receptors
Caspases
Adenosine A3 Receptor Agonists
Caspase 3
Myocardial Infarction

Activities 1996 2015

  • 14 Participation in conference

British Cardiovascular Society conference

Maddock, H. (Keynote Speaker)
8 Jun 201510 Jun 2015

Activity: Participation in conference

Coventry University, HLS Research Symposium

Maddock, H. (Keynote Speaker)
1 Apr 2015

Activity: Participation in conference

Boehringer Ingelheim, Germany Research Symposium

Maddock, H. (Keynote Speaker)
1 Feb 2015

Activity: Participation in conference

British Toxicology Society

Maddock, H. (Speaker)
2 Feb 2012

Activity: Participation in conference

British Toxicology Society Spring conference

Maddock, H. (Speaker)
5 May 2012

Activity: Participation in conference